U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07151157) titled 'Therapeutic Value of Sirolimus in Refractory Adult-Onset Still's Disease' on Aug. 24.
Brief Summary: This study aims to further evaluate the anti-inflammatory effects of the mTOR inhibitor sirolimus in patients with adult-onset Still's disease (AOSD), and to verify whether it can reduce inflammation and control disease activity by restoring ZFP36L2 expression and promoting the degradation of inflammatory cytokine mRNAs. A total of three patients with refractory AOSD will be enrolled, defined as those showing no significant improvement after treatment with glucocorticoids at 1 mg/kg, or experiencing relapse during tapering of glucoco...